The date received by manufacturer has been used for this field.The manufacturing location for this product is (b)(6).This site is not registered with the fda.Therefore the manufacturing site (b)(4) was used.A device evaluation is anticipated, but has not yet begun.Upon completion of the investigation, a supplemental report will be filed.
|
Investigation results: bd (b)(4) received 5 representative samples from the customer facility for investigation.Customer return samples are intact and did not show any evidence of abnormality in package or product which can lead to sterility compromise and cause reaction / phlebitis.Bd visually inspected 100 retain samples for any damage on the primary packaging, catheter & cannula tip for lot# 17a0341h.All samples found in ok condition.The complaint history for the lot# 17a0341h was reviewed and up to the reported incident date no complaint had been registered against the above lot in terms of package integrity and sterility compromise which may cause reaction / phlebitis.Dhr was reviewed for the product test.The entire routing test for reported lot found within the specification limit.No discrepancy was reported and recorded in dhr in customer reported lot # 17a0341h.The team inspected the customer return samples, in which no any manufacturing defect observed in terms of package integrity, seal strength and sterility compromise.The team investigated the test records of customer reported lot number, the product conform to sterility specification.The team also checked the seal strength of the unit pack performed in routine testing, the results were acceptable and conforms to specification limit of the product.The defect is not confirmed.Conclusions: the exact root cause is not identified.Based on an evaluation of severity and occurrence, it was determined that no corrective action is required.
|